[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602823":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":58,"collaborators":61,"id":64,"slug":23,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":23,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":23,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":90,"whyStopped":23,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment with Ketone Supplement","EXPERIMENTAL","Participants (n=25) will receive three doses of a ketone supplement drink daily for seven days.",[13],"Dietary Supplement: Treatment with Ketone Supplement",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment with Placebo","Participants (n=25) will receive three doses of a placebo drink daily for seven days.",[18],"Dietary Supplement: Treatment with Placebo",[20,24],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":23},"DIETARY_SUPPLEMENT",[9],null,{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":23},"Participants (n=25) will receive three doses of a placebo drink for seven days.",[15],[28],{"name":29,"affiliation":5,"role":30},"Peter Manza, PhD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":23,"email":35},"CONTACT","410-706-2814","peter.manza@som.umaryland.edu",{"name":37,"role":33,"phone":38,"phoneExt":23,"email":39},"Kynah Walston, MA","443-974-7951","Kynah.Walston@som.umaryland.edu",[41],{"facility":42,"status":23,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Caron Pennsylvania Addiction Treatment and Rehab Center","Wernersville","Pennsylvania","19565","United States",{"type":48,"coordinates":49},"Point",[50,51],-76.0805,40.33009,{"lat":51,"lon":50},[54],{"name":55,"role":33,"phone":56,"phoneExt":23,"email":57},"Erin Deneke, PhD","610-743-6242","edeneke@caron.org",{"type":30,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Peter Manza","Assistant Professor",[62],{"name":63,"class":6},"Caron Treatment Centers","100602823",false,"NCT07128524","Ketones for Opioid Craving","Ketone Supplementation for Opioid Craving and Withdrawal","Inclusion Criteria:\n\n* Age 18-75 years\n* Meets currents DSM-5 criteria for OUD and admitted for opioid withdrawal management treatment at Caron Treatment Center\n* Willingness to provide signed, informed consent and commit to completing the procedures in the study\n\nExclusion Criteria:\n\n* Current severe gastrointestinal (GI), liver, or other clinically significant physical disease that may interfere with the intake of the ketone supplement (e.g., sever inflammatory bowel disease, cirrhosis).\n* Currently taking (within the past two weeks) GLP-1 receptor agonist medications, e.g. semaglutide, which can interfere with the absorption of the ketone supplement\n* Currently pregnant or lactating, for people of childbearing potential\n* Judged by the principal investigator. study physician, or their designee to be an unsuitable candidate for the study","ALL","18 Years","75 Years",{"count":74,"type":75},50,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The goal of this clinical trial is to learn if ketone supplementation (KS) works to reduce craving for opioids for adults with opioid use disorder (OUD) undergoing in-patient acute withdrawal management. The main questions it aims to answer are:\n\n* Does KS reduce craving for opioids in patients with opioid use disorder?\n* Does KS reduce symptoms of opioid withdrawal such as low mood and pain? Researchers will compare KS to a placebo to see if KS works to reduce craving for opioids and reduce withdrawal symptoms in adults entering in-patient acute withdrawal management for opioid use disorder.\n\nParticipants will:\n\n* Be given KS or a placebo three (3) times daily for seven (7) days\n* Complete mood, pain tolerance, and subjective opioid withdrawal assessments",[81],"Opioid Use Disorder",[83,84,85,86,87,88,89],"opioid use disorder","OUD","ketone","ketone supplement","ketone supplementation","craving","withdrawal","NOT_YET_RECRUITING","2026-06-30",{"date":93,"type":94},"2026-07-02","ACTUAL",{"date":96,"type":75},"2026-07",{"date":98,"type":75},"2027-09",{"name":5,"class":6},1]